I agree that this site is using cookies. You can find further informations here.
X
Mahon, François-Xavier
252  results:
Search for persons X
?
1

How to interpret the EURO-SKI study and its treatment-free ..:

Pfirrmann, Markus ; Saussele, Susanne ; Mahon, François-Xavier.
Leukemia.  38 (2024)  2 - p. 460-462 , 2024
Link: https://doi.org/10.1038/..
 
?
2

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STU..:

Hochhaus, Andreas ; Saussele, Susanne ; Mahon, Francois-Xavier...
HemaSphere.  7 (2023)  S3 - p. e5851092 , 2023
Link: https://doi.org/10.1097/..
 
?
3

Asciminib monotherapy in patients with CML-CP without BCR::..:

Mauro, Michael J. ; Hughes, Timothy P. ; Kim, Dong-Wook...
Leukemia.  37 (2023)  5 - p. 1048-1059 , 2023
Link: https://doi.org/10.1038/..
 
?
4

POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomiz..:

Strickland, Stephen ; Andorsky, David ; Brümmendorf, Tim...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S178 , 2023
Link: https://doi.org/10.1016/..
 
?
5

S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRON..:

Efficace, Fabio ; Mahon, Francois-Xavier ; Richter, Johan...
HemaSphere.  7 (2023)  S3 - p. e0972454 , 2023
Link: https://doi.org/10.1097/..
 
?
6

S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONS..:

Pfirrmann, Markus ; Mahon, Francois-Xavier ; Dulucq, Stéphanie...
HemaSphere.  7 (2023)  S3 - p. e230884b , 2023
Link: https://doi.org/10.1097/..
 
?
7

CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study..:

Strickland, Stephen ; Andorsky, David ; Brümmendorf, Tim...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S349-S350 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Imatinib Optimized Therapy Improves Major Molecular Respons..:

Johnson-Ansah, Hyacinthe ; Maneglier, Benjamin ; Huguet, Françoise...
Pharmaceutics.  14 (2022)  8 - p. 1676 , 2022
Link: https://doi.org/10.3390/..
 
?
9

Poster: CML-466 Asciminib Provides Durable Molecular Respon..:

Hughes, Timothy P. ; Cortes, Jorge E. ; Réa, Delphine...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S146 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Onset of blast crisis in chronic myeloid leukemia patients ..:

Dulucq, Stephanie ; Hayette, Sandrine ; Cayuela, Jean-Michel...
Haematologica.  107 (2022)  12 - p. 2944-2949 , 2022
Link: https://doi.org/10.3324/..
 
?
11

CML-466 Asciminib Provides Durable Molecular Responses in P..:

Hughes, Timothy P. ; Cortes, Jorge E. ; Réa, Delphine...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S300 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Kinetics of early and late molecular recurrences after firs..:

Dulucq, Stéphanie ; Nicolini, Franck E. ; Rea, Delphine...
Haematologica.  107 (2022)  12 - p. 2859-2869 , 2022
Link: https://doi.org/10.3324/..
 
?
13

Antimetabolic cooperativity with the clinically approved l-..:

Trinh, Anne ; Khamari, Raeeka ; Fovez, Quentin...
Molecular Metabolism.  55 (2022)  - p. 101410 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Discontinuation or Cessation of Tyrosine Kinase Inhibitor T..:

, In: Hematologic Malignancies; Chronic Myeloid Leukemia,
Saußele, Susanne ; Mahon, Francois-Xavier - p. 265-273 , 2021
Link: https://doi.org/10.1007/..
 
?
15

Molecular status 36 months after TKI discontinuation in CML..:

Richter, Johan ; Lübking, Anna ; Söderlund, Stina...
Leukemia.  35 (2021)  8 - p. 2416-2418 , 2021
Link: https://doi.org/10.1038/..
 
1-15